Bayer secures full ownership of Bayer Zydus Pharma

Published On 2024-05-03 06:00 GMT   |   Update On 2024-05-03 06:00 GMT

Mumbai: Bayer Pharmaceuticals Private Limited and Zydus Lifesciences Limited (formerly Cadila Healthcare) have announced the successful conclusion of their joint venture (JV) - Bayer Zydus Pharma Private Limited (BZPPL). The 50:50 joint venture was established on January 28, 2011, for the sales and marketing of pharmaceutical products in India. Bayer is now securing full ownership of the entity, as per pre-agreed JV terms.

Advertisement

The Joint venture successfully leveraged the strengths of both companies to better serve the fast-growing Indian market. It combined Zydus's strong Indian marketing, sales expertise, wide distribution reach and rich industry network, with Bayer’s global expertise in commercializing novel products and bringing in innovation to India. BZPPL made remarkable strides in various therapies including cardiovascular diseases, diabetes, women’s health, ophthalmology and oncology.

Read also: Dr Reddy's Labs, Bayer collaborate to market, distribute second brand of heart failure drug Vericiguat in India

Commenting on the conclusion of the joint venture, Shweta Rai, Managing Director - India and Country Division Head - South Asia, Bayer's Pharmaceuticals division, said, “Zydus Lifesciences has been a formidable partner in our joint mission towards introducing best-in-class innovative health solutions and addressing the unmet healthcare needs of patients in India. As we assume full ownership of BZPPL, Bayer remains committed to ensuring its steadfast presence in India. Building on the gains made over more than a decade, we aim to carry forward our mission of ‘Health for All, Hunger for None’."

Read also: Bayer, Google Cloud to accelerate development of AI-powered healthcare applications for radiologist

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In fiscal 2023, the Group employed around 100,000 people and had sales of 47.6 billion euros. R&D expenses before special items amounted to 5.8 billion euros.
Tags:    

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News